瑞舒伐他汀对2型糖尿病合并高脂血症患者调脂及降低炎症因子水平的作用

目的 观察瑞舒伐他汀对2型糖尿病合并高脂血症患者调脂及降低白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)及C反应蛋白(CRP)水平的作用.方法 42例2型糖尿病并高脂血症患者,口服瑞舒伐他汀10 mg/d,疗程4周,观察治疗前后血脂及IL-6、TNF-α及CRP水平.结果 治疗后患者血清TC、TG、LDL-C均有明显下降(4.3±1.8) mol/L比(6.2±2.0) mol/L；(1.5±0.8)mol/L比(2.4±1.3) mol/L；(2.3 ±0.8)mol/L比(3.2±0.8)mol/L],差异有统计学意义(均P＜0.05)；治疗后所有患者的IL-6、TNF-α 及CRP均较治疗前下降分别为(27.2±12.6) μg/L比(60.5 ±20.3)μg/L；(0.21 ±0.15) μg/L比(0.32±0.09) μg/L；(4.91 ±0.13) mg/L比(5.87 ±0.21 )mg/L,均P＜0.05].结论 瑞舒伐他汀可有效降低糖尿病高脂血症患者的血脂水平,亦可明显降低炎症因子水平,有利于改善糖尿病大血管病变.

The effects of rosuvastatin on regulating blood lipid level and inflammation factor levels in diabetes patient with hyperlipidemia

Objective To observe the effects of rosuvastatin on regulating blood lipid level and serum inflammation factor levels in diabetes patient with hyperlipidemia, including interleukin-6 （IL-6）, tumor necrosis factor alpha （TNF-a） and C-creactive protein（CRP）. Methods Forty-two cases of type 2 diabetes patients with hyperlipidemia were given rosuvastatin 10mg each night for 4 weeks. Levels of blood lipid, IL-6, CRP and TNF-a were detected before and after treatment. Results After treatment with rosuvastatin ,the serum TC, TG, LDL-C, were significantly decreased （4. 3 ± 1.8 ） mol/L vs （6. 2 ± 2. 0 ） mol/L; （ 1.5 ± 0. 8 ） mol/L vs （2.4 ±1.3 ） mol/L; （ 2. 3 ± 0. 8 ） mol/L vs （ 3.2± 0. 8） mol/L, all P 〈 0. 05 ] , and the serum levels of IL-6, TNF-a and CRP were significantly decreased （27. 2 ± 12. 6） μg/L vs （60. 5 ± 20. 3） μg/L; （0. 21± 0. 15） μg/L vs （0. 32 ± 0.09） μ/L; （4. 91 ±0. 13）mg/L vs （5. 87 ±0. 21 ）mg/L,all P 〈0. 05 ]. Conclusion Rosuvastatin can significantly decrease the levels of blood lioid and serum Inflammation Factor in diabetes patient with hvoerlinidemia.